Francisca FERRER MARÍN

Soler G, Bernal-Vicente A, Antón AI, Torregrosa JM, Caparrós-Pérez E, Sánchez-Serrano I, Martínez-Pérez A, Sánchez-Vega B, Vicente V, Ferrer-Marin F. The JAK2 46/1 haplotype does not predispose to CALR-mutated myeloproliferative neoplasms. Ann Hematol. 2015 May;94(5):789-94. doi: 10.1007/s00277-014-2266-y. PubMed PMID: 25482455.

AÑO: 2015; IF: 3.022

25482455

Gómez-Simón A, Plaza EM, Torregrosa JM, Ferrer-Marín F, Sánchez-Guiu I, Vicente V, Lozano ML, Rivera J. Evaluation of two-step haemoglobin screening with HemoCue for blood donor qualification in mobile collection sites. Vox Sang. 2014 Nov;107(4):343-50. doi: 10.1111/vox.12165. PubMed PMID: 24916720.

AÑO: 2014; IF: 2.347

24916720

Alvarez-Larrán A, Martínez-Avilés L, Hernández-Boluda JC, Ferrer-Marín F, Antelo ML, Burgaleta C, Mata MI, Xicoy B, Martínez-Trillos A, Gómez-Casares MT, Durán MA, Marcote B, Ancochea A, Senín A, Angona A, Gómez M, Vicente V, Cervantes F, Bellosillo B, Besses C. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. Ann Hematol. 2014 Dec;93(12):2037-43. doi: 10.1007/s00277-014-2152-7. PubMed PMID: 24981691.

AÑO: 2014; IF: 2.634

24981691

Torregrosa JM, Ferrer-Marín F, Lozano ML, Moreno MJ, Martinez C, Anton AI, Rivera J, Vicente V. Impaired leucocyte activation is underlining the lower thrombotic risk of essential thrombocythaemia patients with CALR mutations as compared with those with the JAK2 mutation. Br J Haematol. 2016 Mar;172(5):813-5. doi: 10.1111/bjh.13539. Epub 2015 Jun 30. PubMed PMID: 26132594.

AÑO: 2016; IF: 5.67

26132594

Sánchez Guiu IM, Martínez-Martinez I, Martínez C, Navarro-Fernandez J, García-Candel F, Ferrer-Marín F, Vicente V, Watson SP, Andrews RK, Gardiner EE, Lozano ML, Rivera J. An atypical IgM class platelet cold agglutinin induces GPVI-dependent aggregation of human platelets. Thromb Haemost. 2015 Aug;114(2):313-24. doi: 10.1160/TH14-11-0945. PubMed PMID: 25994029.

AÑO: 2015; IF: 4.379

25994029